235 related articles for article (PubMed ID: 15885603)
21. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells.
Schrama D; Terheyden P; Otto K; Kämmerer U; Bröcker EB; Lühder F; Cosman D; Andersen MH; Becker JC
Eur J Immunol; 2006 Jan; 36(1):65-72. PubMed ID: 16342232
[TBL] [Abstract][Full Text] [Related]
22. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
Guo KY; Mei JZ; Yao KT
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
[TBL] [Abstract][Full Text] [Related]
23. The role of the NKG2D receptor for tumor immunity.
Coudert JD; Held W
Semin Cancer Biol; 2006 Oct; 16(5):333-43. PubMed ID: 16914326
[TBL] [Abstract][Full Text] [Related]
24. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands.
Kaiser BK; Yim D; Chow IT; Gonzalez S; Dai Z; Mann HH; Strong RK; Groh V; Spies T
Nature; 2007 May; 447(7143):482-6. PubMed ID: 17495932
[TBL] [Abstract][Full Text] [Related]
25. Tumor-derived soluble MICs impair CD3(+)CD56(+) NKT-like cell cytotoxicity in cancer patients.
Wang H; Yang D; Xu W; Wang Y; Ruan Z; Zhao T; Han J; Wu Y
Immunol Lett; 2008 Oct; 120(1-2):65-71. PubMed ID: 18672004
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
[TBL] [Abstract][Full Text] [Related]
27. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2.
Clayton A; Mitchell JP; Court J; Mason MD; Tabi Z
Cancer Res; 2007 Aug; 67(15):7458-66. PubMed ID: 17671216
[TBL] [Abstract][Full Text] [Related]
28. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
[TBL] [Abstract][Full Text] [Related]
29. NKG2D and natural cytotoxicity receptors are involved in natural killer cell interaction with self-antigen presenting cells and stromal cells.
Poggi A; Prevosto C; Zancolli M; Canevali P; Musso A; Zocchi MR
Ann N Y Acad Sci; 2007 Aug; 1109():47-57. PubMed ID: 17785290
[TBL] [Abstract][Full Text] [Related]
30. Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus.
Sáez-Borderías A; Gumá M; Angulo A; Bellosillo B; Pende D; López-Botet M
Eur J Immunol; 2006 Dec; 36(12):3198-206. PubMed ID: 17109473
[TBL] [Abstract][Full Text] [Related]
31. NKG2D ligands: key targets of the immune response.
González S; López-Soto A; Suarez-Alvarez B; López-Vázquez A; López-Larrea C
Trends Immunol; 2008 Aug; 29(8):397-403. PubMed ID: 18602338
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
[TBL] [Abstract][Full Text] [Related]
33. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
34. NKG2D and cytotoxic effector function in tumor immune surveillance.
Hayakawa Y; Smyth MJ
Semin Immunol; 2006 Jun; 18(3):176-85. PubMed ID: 16675266
[TBL] [Abstract][Full Text] [Related]
35. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.
Jinushi M; Takehara T; Tatsumi T; Hiramatsu N; Sakamori R; Yamaguchi S; Hayashi N
J Hepatol; 2005 Dec; 43(6):1013-20. PubMed ID: 16168521
[TBL] [Abstract][Full Text] [Related]
36. MICA antigens stimulate T cell proliferation and cell-mediated cytotoxicity.
Zhang Y; Stastny P
Hum Immunol; 2006 Mar; 67(3):215-22. PubMed ID: 16698445
[TBL] [Abstract][Full Text] [Related]
37. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142.
Chalupny NJ; Rein-Weston A; Dosch S; Cosman D
Biochem Biophys Res Commun; 2006 Jul; 346(1):175-81. PubMed ID: 16750166
[TBL] [Abstract][Full Text] [Related]
39. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.
Mamessier E; Sylvain A; Bertucci F; Castellano R; Finetti P; Houvenaeghel G; Charaffe-Jaufret E; Birnbaum D; Moretta A; Olive D
Cancer Res; 2011 Nov; 71(21):6621-32. PubMed ID: 21937679
[TBL] [Abstract][Full Text] [Related]
40. The effect of silencing NKG2D through RNA interference on receptor functions in interleukin-2-activated human natural killer cells.
Baeriswyl V; Wodnar-Filipowicz A; Kalberer CP
Haematologica; 2006 Nov; 91(11):1538-41. PubMed ID: 17043026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
